Alloy Therapeutics Inc., a biotechnology ecosystem company, has joined forces with Pfizer Inc., to develop a new platform ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), announced ...

The HCAb Harbour Mice® platform is revolutionizing antibody development by producing unique heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering ...

Alexion Pharmaceuticals v Amgen (UPC_Coa-405/2024) and Alexion Pharmaceuticals v Samsung Bioepis NL BV (UPC_CoA-402/2024); December 20, 2024.

In the field of biopharmaceuticals, every technological innovation has the potential to revolutionize treatment strategies. Sanyou Bio's Intelligent Hundred-Trillion Molecule Library (AI-STAL) has ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

The antibody molecule in particular has been ... the reassembly of naturally occurring genes encoding the heavy- and light-chain domains from either immune 1,2 or nonimmune B-cell sources 3 ...

Thus, I believe it is highly critical to go over this aspect. For starters, it is not a traditional IgG antibody or heavy-chain only antibody. It is instead a Nanobody, which is a single-domain ...

Notably, the comprehensive nature of the FR library, encompassing a wide array of human heavy and light chain germline genes, renders this method applicable across various antibody targets.